<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 

HER2+ PDX Models 
A Champions Model Cohort

A meticulously curated bank of Patient-Derived Xenograft (PDX) HER2/ERBB2 models, directly established from patient biopsies, featuring well-documented treatment histories, genomic mutations, and clinical characteristics. 

 

 

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

Patient-derived Xenograft (PDX) HER2/ERBB2 Gene Model Solutions

Champions Oncology has developed a cutting-edge cohort of HER2/ERBB2 Patient-derived Xenograft models, delivering a full-spectrum approach to HER2/ERBB2 cancers, including breast, gastric, and salivary duct carcinomas, as well as in other forms of cancer. Our bank consists of a large bank of approximately 1400* extensively characterized patient-derived xenograft (PDX) models for oncology drug development. Our models are well-annotated with patient treatment history and molecular characterizations such as mutations, gene expression, and copy number variations of the HER2 family of genes. (*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading HER2+ cohort showcases low-passage PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access to a large bank of HER2+ PDX models with clinically relevant molecular and pathological characteristics.
  • Access to highly characterized models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
  • Includes models pretreated with advanced therapies such as immunotherapies, small molecule inhibitors, and more.